The DOI matches its Crossref record; 244 of the 246 references it cites were found in a registry or an index.
Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children
Open accessAbstract
Background.: Individuals infected with Mycobacterium tuberculosis (Mtb) may develop symptoms and signs of disease (tuberculosis disease) or may have no clinical evidence of disease (latent tuberculosis infection [LTBI]). Tuberculosis disease is a leading cause of infectious disease morbidity and mortality worldwide, yet many questions related to its diagnosis remain. Methods.: A task force supported by the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America searched, selected, and synthesized relevant evidence. The evidence was then used as the basis for recommendations about the diagnosis of tuberculosis disease and LTBI in adults and children. The recommendations were formulated, written, and graded using the Grading, Recommendations, Assessment, Development and Evaluation (GRADE) approach. Results.: Twenty-three evidence-based recommendations about diagnostic testing for latent tuberculosis infection, pulmonary tuberculosis, and extrapulmonary tuberculosis are provided. Six of the recommendations are strong, whereas the remaining 17 are conditional. Conclusions.: These guidelines are not intended to impose a standard of care. They provide the basis for rational decisions in the diagnosis of tuberculosis in the context of the existing evidence. No guidelines can take into account all of the often compelling unique individual clinical circumstances.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, culture may lead to misclassification of some cases of extrapulmonary tuberculosis as ‘not tuberculosis', owing to the paucibacillary nature of the disease.”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Lewinsohn 2017
In the citing paper
“This means that culture may have low sensitivity for extrapulmonary tuberculosis overall and further that culture sensitivity may differ for different forms of extrapulmonary tuberculosis (Lewinsohn 2017).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Lewinsohn 2017
In the citing paper
“A recent evidence synthesis reported sensitivities of 72% to 88% in lymph node tissue, 28% to 81% in pleural fluid, 90% in pleural tissue, and 31% to 56% in CSF. Specificity ranged from 90% to 100% (Lewinsohn 2017).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Lewinsohn 2017
In the citing paper
“For the 'Summary of findings' tables for CSF and pleural fluid, we provide evidence using culture as the reference standard, which is considered the best reference standard for tuberculosis (Lewinsohn 2017).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Lewinsohn 2017
Citations
Cites
Global tuberculosis report (2014)
Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309 · cited 3×
“These assays are promising, but are not yet commercially available [146, 159, 160].”
BackgroundMethodGrading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
Gandhi, N. R., Moll, A., Sturm, A. W., Pawinski, R., Govender, T., Lalloo, U., Zeller, K., Andrews, J., & Friedland, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69573-1 · Cited by 1,732 · cited 1×
“The emergence of drug-resistant tuberculosis has become apparent over the past 2 decades, and in particular, multidrug-resistant tuberculosis (MDR-TB; resistant to isoniazid and rifampin) and extensively drug-resistant tuberculosis (XDR-TB; resistant to isoniazid and rifampin, plus any fluoroquinolone and at least 1 o…”
BackgroundSelwyn, P. A., Hartel, D., Lewis, V. A., Schoenbaum, E. E., Vermund, S. H., Klein, R. S., Walker, A. T., & Friedland, G. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903023200901 · Cited by 1,574 · cited 1×
“For example, individuals who have a prior latent infection with Mtb (not treated) and then acquire HIV infection will develop TB disease at an approximate rate of 5%–10% per year (in the absence of effective HIV treatment) [18, 19].”
Background(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.16141 · Cited by 1,525
(2005) · PsycEXTRA Dataset · doi:10.1037/e545842006-001 · Cited by 1,274
Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes
Woods, G. L., Brown‐Elliott, B. A., Conville, P. S., Desmond, E. P., Hall, G. S., Lin, G., Pfyffer, G. E., Ridderhof, J. C., Siddiqi, S. H., Wallace, R. J., et al. (2011) · Cited by 1,136
Self-citationMolecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis
Mahairas, G. G., Sabo, P. J., Hickey, M. J., Singh, D. C., & Stover, C. K. (1996) · Journal of Bacteriology · doi:10.1128/jb.178.5.1274-1282.1996 · Cited by 1,103
Research works printed but not linked: 8
- World Health Organization, 2015, Global tuberculosis report 2015
- T-SPOT.TB: an aid in the diagosis of tuberculosis infection; package insert for in vitro diagnositic use
- Perez, 2005, Impact of screening for latent TB before initiating anti-TNF therapy in North America and Europe, Ann Rheum Dis, 64, 265
- US Food and Drug Administration, 2008, Medical devices: T-SPOT-TB—P070006
- Forbes, 2008, Laboratory detection and identification of mycobacteria; approved guideline
- Francis J. Curry National Tuberculosis Center and California Department of Public Health, 2008, Drug-resistant tuberculosis: a survival guide for clinicians
- World Health Organization, 2008, Molecular line probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis (MDR-TB)
- Ena, 1990, The usefulness and limitations of adenosine deaminase in the diagnosis of tubercular pleurisy. A meta-analytical study [in Spanish], Med Clin (Barc), 95, 333
Cited by
Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
“A cytokine release assay analogous to the tuberculosis IFNg release assay is a possibility (Lewinsohn et al., 2017; Murugesan et al., 2020; Petrone et al., 2020), as are plasmaCXCL10 (Rydyznski Moderbacher et al.”
Miller, J. M., Binnicker, M. J., Campbell, S., Carroll, K. C., Chapin, K. C., Gilligan, P. H., Gonzalez, M. D., Jerris, R. C., Kehl, S. C., Patel, R., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy381 · Cited by 641
“The figures for free IFN-λ were ≥89% and ≥97% for sensitivity and specificity, respectively [121].”
BackgroundMethodThe global prevalence of latent tuberculosis: A systematic review and meta-analysis
Cohen, A., Mathiasen, V. D., Schön, T., & Wejse, C. (2019) · European Respiratory Journal · doi:10.1183/13993003.00655-2019 · Cited by 547
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
“The WHO-recommended standardized shorter-course 9-to 11-month regimen for MDR-TB was estimated by the guidelines committee to have minimal desirable effects (on treatment success, mortality, culture conversions) and small to moderate undesirable effects (adverse events, the use of drugs for which there is documented o…”
InfluentialSelf-citationMiller, J. M., Binnicker, M. J., Campbell, S., Carroll, K. C., Chapin, K. C., Gilligan, P. H., Gonzalez, M. D., Jerris, R. C., Kehl, S. C., Patel, R., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy584 · Cited by 449
“The figures for free IFN-λ were ≥89% and ≥97% for sensitivity and specificity, respectively [121].”
BackgroundMethod
Metadata
- Authors
- Lewinsohn, D. M., Leonard, M. K., LoBue, P. A., Cohn, D. L., Daley, C. L., Desmond, E., Keane, J., Lewinsohn, D. A., Loeffler, A. M., Mazurek, G. H., O’Brien, R. J., Pai, M., Richeldi, L., Salfinger, M., Shinnick, T. M., Sterling, T. R., Warshauer, D. M., & Woods, G. L.
- Affiliations
- Oregon Health & Science University (US)
- Emory University School of Medicine and
- Centers for Disease Control and Prevention (US)
- Denver Public Health (US)
- National Jewish Health (US)
- California Department of Public Health (US)
- St. James's Hospital (IE)
- Francis J. Curry International TB Center, San Francisco, California;
- FIND (CH)
- McGill University (CA)
- University of Southampton (GB)
- Vanderbilt University (US)
- Wisconsin State Laboratory of Hygiene, Madison, and
- University of Arkansas for Medical Sciences (US)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-12-08
- Volume
- 64
- Issue
- 2
- Pages
- e1-e33
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC5504475
- OpenAlex
- W2559832962
- Cited by
- 992
- References
- 246
- Citations by year
- 2026: 65 · 2025: 81 · 2024: 91 · 2023: 101 · 2022: 115 · 2021: 142 · 2020: 133 · 2019: 110 · 2018: 96 · 2017: 55 · 2016: 1
- FWCI
- 80.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Arrow@dit (Dublin Institute of Technology) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Infectious Diseases › Diagnosis and treatment of tuberculosis
- Keywords
- tuberculosis diagnosis, latent tuberculosis infection, pulmonary tuberculosis, extrapulmonary tuberculosis, Mycobacterium tuberculosis, diagnostic testing, children, adults
- MeSH terms
- Adult, Age Factors, Child, Humans, Mycobacterium tuberculosis, Tuberculosis, Tuberculosis, Pulmonary, Latent Tuberculosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. https://app.cochat.ai/papers/10.1093/cid/ciw694
- The paper
- Lewinsohn, D. M., Leonard, M. K., LoBue, P. A., Cohn, D. L., Daley, C. L., Desmond, E., Keane, J., Lewinsohn, D. A., Loeffler, A. M., Mazurek, G. H., O’Brien, R. J., Pai, M., Richeldi, L., Salfinger, M., Shinnick, T. M., Sterling, T. R., Warshauer, D. M., & Woods, G. L. (2017). Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciw694
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.